Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00271167 · ClinicalTrials.gov registry record · Phase 2
A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass
A Phase 2 study, sponsored by Inotek Pharmaceuticals Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
NCT00271167: Clinical Trial Phase 2 study, sponsored by Inotek Pharmaceuticals Corporation.
NCT00271167 is a Phase 2 study that was terminated before completion, run by Inotek Pharmaceuticals Corporation. The registered enrollment target is 162 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00271167, a Phase 2 study, was terminated before completion, sponsored by Inotek Pharmaceuticals Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of INO-1001, an intravenous PARP (poly-\[ADP ribose\] polymerase) inhibitor, in patients undergoing heart surgery. The study also measures whether INO-1001 reduces the side effects caused by heart-lung bypass machines.
Interventions
- DRUG INO-1001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Why NCT00271167 stopped before completion
NCT00271167 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 1 intervention - of which INO-1001 is the first listed.
NCT00271167 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00271167 about?
NCT00271167 is a clinical study titled "A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass". The purpose of this study is to assess the safety of INO-1001, an intravenous PARP (poly-\[ADP ribose\] polymerase) inhibitor, in patients undergoing heart surgery. The study also measures whether INO-1001 reduces the side effects caused by heart-lung bypass machines.
What is the current status of trial NCT00271167?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2005-10. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00271167?
The interventions under investigation include: INO-1001 (DRUG).
Who is sponsoring clinical trial NCT00271167?
This trial is sponsored by Inotek Pharmaceuticals Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00271167's enrollment target sits among peer trials
162 418th of 2000 higher than 1,579 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia